Allurion Technologies (ALUR) to Release Earnings on Wednesday

Allurion Technologies (NYSE:ALUR) is projected to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Allurion Technologies to post earnings of ($0.34) per share and revenue of $3.10 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 20, 2026 at 8:30 AM ET.

Allurion Technologies Stock Performance

Shares of NYSE ALUR opened at $0.71 on Tuesday. The stock has a fifty day moving average price of $0.72 and a two-hundred day moving average price of $1.22. The firm has a market cap of $10.64 million, a P/E ratio of -0.07 and a beta of -0.18. Allurion Technologies has a 1 year low of $0.23 and a 1 year high of $3.42.

Institutional Investors Weigh In On Allurion Technologies

A number of institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP lifted its position in shares of Allurion Technologies by 131.7% during the 4th quarter. RTW Investments LP now owns 5,891,430 shares of the company’s stock valued at $7,246,000 after acquiring an additional 3,348,827 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Allurion Technologies during the 4th quarter valued at $74,000. Heights Capital Management Inc. acquired a new stake in shares of Allurion Technologies during the 4th quarter valued at $74,000. Armistice Capital LLC acquired a new position in shares of Allurion Technologies in the 4th quarter valued at $74,000. Finally, State Street Corp boosted its position in shares of Allurion Technologies by 76.2% in the 4th quarter. State Street Corp now owns 26,135 shares of the company’s stock valued at $32,000 after purchasing an additional 11,300 shares during the period. Institutional investors and hedge funds own 21.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allurion Technologies in a research note on Wednesday, January 21st. Chardan Capital set a $3.00 target price on Allurion Technologies and gave the stock a “buy” rating in a report on Tuesday, February 24th. Finally, Loop Capital set a $3.00 target price on Allurion Technologies in a report on Tuesday, February 24th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $3.00.

About Allurion Technologies

Allurion Technologies is a medical technology company specializing in non-surgical weight-loss solutions. The company’s flagship product, the Allurion Gastric Balloon, is a swallowable, fluid-filled device designed to promote weight loss by creating a sense of fullness in the stomach. Unlike traditional intragastric balloons, the Allurion device does not require endoscopic insertion or removal, as it self-deflates and is naturally expelled after treatment, simplifying the patient experience and reducing clinical resource requirements.

In addition to its gastric balloon, Allurion has developed a comprehensive digital health platform that integrates wireless tracking devices, a mobile application, and remote coaching to support patients throughout their weight-loss journey.